ClinicalTrials.gg
CompletedNCT02945475Updated Apr 20, 2021

Neural Mechanisms for Appetitive Responses to High Reward Foods

An observational study in Appetitive Behavior and Obesity, sponsored by University of Southern California. Completed at 1 site in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-20.

Sponsored by University of Southern California · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
114
Ages
18 Years to 35 Years
Sex
All
01

Study summary

This study is aimed at understanding neuroendocrine responses to different types of sugars and how this influences feeding behavior among lean, overweight, and obese individuals.

Read the detailed description

The investigators have previously combined functional magnetic resonance imaging (fMRI) with hormonal and behavioral assessments to better understand the impacts of glucose and fructose on appetite and its central regulation in humans and have made important observations in lean individuals linking fructose consumption to overeating and obesity. The investigators now propose to expand this work by examining the impacts of glucose and fructose ingested together (sucrose), as occurs in real life, and by examining effects of a common non-nutritive sweetener, sucralose, on brain and appetitive response. The investigators propose a random-order crossover design to determine the effects of caloric and non-nutritive sweeteners among lean, overweight, and obese participants. The investigators will measure circulating levels of hormones involved in satiety signaling, quantify food intake, and measure brain activity using blood-oxygen level dependent and arterial spin labeling methods and functional connectivity analyses.

02

Conditions studied

  • Appetitive Behavior
  • Obesity

Keywords

  • functional magnetic resonance imaging
  • eating behavior
  • sugar
03

In context

Obesity

6,570 studies on the registry are indexed under Obesity; 1,718 are open to participants now.

This study's enrollment of 114 is below the median of 132 across 1,338 observational studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University of Southern California is the lead sponsor of 789 studies on the registry; 136 are open to participants now.

Of its 69 completed or terminated interventional studies of FDA-regulated products, 32 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants in the greater Los Angeles area will be recruited. Lean, overweight, and obese participants will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-35 years, right-handed, weight change \<2% for at least 3 months prior to participation, no history of diabetes or other significant medical problems, fasting glucose \<126 mg/dl.
  • Lean group: BMI of 19-24.9 kg/m2
  • Obese Group: BMI 30-40 kg/m2
  • Overweight Group: BMI of 25-29.9 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Neurological, psychiatric or addiction disorder, fasting glucose ≥126 mg/dl, use of prescription medication (with the exception of contraceptives), tobacco use, contraindications to MRI scanning (detailed in Protection of Human Subjects), fructose intolerance, history of eating disorder, actively trying to lose weight.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
114 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • obese

    Individuals ages 18 to 35 years of age with body mass index (BMI) 30-40 kg/m2

  • lean

    Individuals ages 18 to 35 years of age with BMI of 19-24.9 kg/m2

  • overweight

    Individuals ages 18 to 35 years of age with BMI of 25-29.9 kg/m2

06

What researchers measure

Primary outcomes

  1. Changes of Blood oxygen level-dependent (BOLD) signal responses to food vs non-food cues after ingestion of different types of sugar. BOLD signal responses to food cues will be compared at the level of whole brain and within a priori regions of interest.

    These will be compared between ingestion of drinks and at level of whole brain and in regions of interest

    Time frame: Sessions 1, 2, 3, 4

  2. Cerebral Blood Flow Response

    Arterial spin labeling with be used to determine brain areas with relative increases or decreases in CBF after ingestion of sucrose, glucose, or sucralose.

    Time frame: Sessions 1, 2, 3, 4

  3. Systemic Metabolite and Hormone Responses

    The effects of sugar ingestion on changes in systemic metabolite (glucose) and hormone (insulin, GLP-1, leptin, ghrelin, peptide YY) levels will be assessed.

    Time frame: Sessions 1, 2, 3, 4

Secondary outcomes

  1. Functional Connectivity between regions involved in regulation of food intake

    Investigators will perform a physiological-psychological-interaction (PPI) analysis using the nucleus accumbens as the seed to explore brain regions showing increased functional connectivity to the seed during the food-cue task.

    Time frame: Sessions 1, 2, 3, 4

  2. Appetite Ratings

    Ratings of hunger and desire for food in response to food vs non-food cues will be analyzed using a repeated-measures ANOVA with condition (glucose, sucrose, sucralose) and stimulus (food vs non-food) as within-subject factors.

    Time frame: Sessions 1, 2, 3, 4

  3. Ad Libitum Food Intake

    Total calories consumed and percent calories from sugar, fat and protein will be compared between conditions.

    Time frame: Sessions 1, 2, 3, 4

07

Study locations

1 site
  • Alexandra Yunker
    Los Angeles, California 90089, United States
08

References and documents

Publications

  • Chakravartti SP, Jann K, Veit R, Liu H, Yunker AG, Angelo B, Monterosso JR, Xiang AH, Kullmann S, Page KA. Non-caloric sweetener effects on brain appetite regulation in individuals across varying body weights. Nat Metab. 2025 Mar;7(3):574-585. doi: 10.1038/s42255-025-01227-8. Epub 2025 Mar 26. PubMed 40140714 ↗
  • Smith A, Page KA, Smith KE. Associations between affect dynamics and eating regulation in daily life: a preliminary ecological momentary assessment study. Cogn Emot. 2024 Aug;38(5):818-824. doi: 10.1080/02699931.2024.2323478. Epub 2024 Mar 1. PubMed 38427387 ↗
  • Alves JM, Yunker AG, Luo S, Jann K, Angelo B, DeFendis A, Pickering TA, Smith A, Monterosso JR, Page KA. FGF21 response to sucrose is associated with BMI and dorsal striatal signaling in humans. Obesity (Silver Spring). 2022 Jun;30(6):1239-1247. doi: 10.1002/oby.23432. Epub 2022 May 2. PubMed 35491674 ↗
  • Yunker AG, Alves JM, Luo S, Angelo B, DeFendis A, Pickering TA, Monterosso JR, Page KA. Obesity and Sex-Related Associations With Differential Effects of Sucralose vs Sucrose on Appetite and Reward Processing: A Randomized Crossover Trial. JAMA Netw Open. 2021 Sep 1;4(9):e2126313. doi: 10.1001/jamanetworkopen.2021.26313. PubMed 34581796 ↗
  • Yunker AG, Luo S, Jones S, Dorton HM, Alves JM, Angelo B, DeFendis A, Pickering TA, Monterosso JR, Page KA. Appetite-Regulating Hormones Are Reduced After Oral Sucrose vs Glucose: Influence of Obesity, Insulin Resistance, and Sex. J Clin Endocrinol Metab. 2021 Mar 8;106(3):654-664. doi: 10.1210/clinem/dgaa865. PubMed 33300990 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Mar 2020 and a completion of Mar 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2016
First posted
Oct 26, 2016
Start
Feb 2016
Primary completionActual
Mar 13, 2020
CompletionActual
Mar 13, 2020
Last update
Apr 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02945475
Responsible party
Kathleen Page (Associate Professor of Medicine, University of Southern California) — Principal investigator
First posted
Oct 26, 2016
Start date
Feb 2016
Primary completion
Mar 13, 2020
Completion
Mar 13, 2020
Last update
Apr 20, 2021

Study contacts

Kathleen Page, MD
principal investigator · University of Southern California

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion